GSK (LON:GSK) Receives Buy Rating from Shore Capital

Shore Capital restated their buy rating on shares of GSK (LON:GSK) in a research note released on Wednesday morning, Marketbeat reports.

A number of other research firms have also recently issued reports on GSK. Deutsche Bank Aktiengesellschaft reaffirmed a buy rating and issued a GBX 1,950 ($24.49) price target on shares of GSK in a report on Wednesday, April 17th. Berenberg Bank raised their target price on shares of GSK from GBX 1,650 ($20.73) to GBX 1,820 ($22.86) and gave the stock a buy rating in a report on Wednesday, February 14th. Finally, Barclays reissued an equal weight rating and set a GBX 1,725 ($21.67) target price on shares of GSK in a report on Monday, April 8th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Hold and an average price target of GBX 1,630.63 ($20.48).

GSK Trading Down 0.3 %

LON GSK opened at GBX 1,700 ($21.35) on Wednesday. The company has a fifty day simple moving average of GBX 1,660.86 and a two-hundred day simple moving average of GBX 1,555.08. The stock has a market cap of £69.53 billion, a P/E ratio of 1,420.83, a P/E/G ratio of 1.12 and a beta of 0.27. GSK has a 12-month low of GBX 1,302.60 ($16.36) and a 12-month high of GBX 1,719.80 ($21.60). The company has a current ratio of 0.88, a quick ratio of 0.73 and a debt-to-equity ratio of 140.82.

GSK Cuts Dividend

The firm also recently announced a dividend, which will be paid on Thursday, July 11th. Investors of record on Thursday, May 16th will be issued a dividend of GBX 15 ($0.19) per share. The ex-dividend date is Thursday, May 16th. This represents a dividend yield of 0.9%. GSK’s dividend payout ratio (DPR) is presently 5,333.33%.

Insider Buying and Selling

In other GSK news, insider Emma Walmsley sold 139,792 shares of GSK stock in a transaction on Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.83), for a total value of £2,317,751.36 ($2,911,382.19). In other GSK news, insider Emma Walmsley sold 139,792 shares of GSK stock in a transaction on Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.83), for a total value of £2,317,751.36 ($2,911,382.19). Also, insider Urs Rohner acquired 434 shares of the business’s stock in a transaction on Wednesday, March 20th. The stock was purchased at an average cost of GBX 1,662 ($20.88) per share, with a total value of £7,213.08 ($9,060.52). 1.77% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.